Crystagen is a short synthetic peptide from the Khavinson “bioregulator” family, marketed as an immune-system regulator. It is a different product from the better-known immune-focused Khavinson dipeptides Vilon (Lys-Glu) and Thymogen (Glu-Trp), and is sold mainly as an oral capsule by longevity and biohacking resellers.
Research snapshot
| Peptide category | Khavinson-family short “bioregulator” peptide, marketed as an immune-system regulator |
| Primary research interest | Immune-system tissue/function support (marketed; not independently confirmed) |
| Highest available evidence | Unverified — mechanism/clinical differentiation from Vilon or Thymogen not clearly explained in sources reviewed; vendor-stated sequence could not be confirmed against an independent primary chemical database |
| Human research available | No — no human clinical trial identified |
| Development status | Not in formal pharmaceutical development; sold mainly as an oral capsule by longevity/biohacking resellers |
| Regulatory status | Not an approved drug anywhere |
| Last reviewed | September 2026 |
Technical identity
| Primary name | Crystagen |
| Alternative names | Distinct product from Vilon (Lys-Glu) and Thymogen (Glu-Trp), the better-known immune-focused Khavinson dipeptides |
| Peptide sequence | Most commonly described by vendors as Glu-Asp-Gly (“EDG”); could not be confirmed against an independent primary chemical database |
| Amino-acid length | 3 (tripeptide, per vendor description; not independently confirmed) |
| Molecular formula | Not independently verified in this pass |
| Molecular weight | Not independently verified in this pass |
| CAS Registry Number | Not reliably established |
| PubChem CID | Not reliably established |
| Peptide class | Khavinson-group “bioregulator” peptide line |
| Primary biological target | Not established — proposed immune-tissue activity, not confirmed via primary literature |
| Developer or originator | Vladimir Khavinson’s laboratory, for the broader bioregulator line |
| Development status | Not an approved or registered pharmaceutical anywhere identified in this review |
What it is
Crystagen is part of the same short-peptide bioregulator concept developed by Vladimir Khavinson’s laboratory, proposed to act on immune-system tissue and function, distinct in commercial framing from the thymus-focused dipeptides Vilon and Thymogen that are more commonly cited in the peer-reviewed Khavinson-group literature. Vendor listings most commonly describe Crystagen as the tripeptide Glu-Asp-Gly (“EDG”), though this could not be confirmed against an independent primary chemical database.
How Crystagen is meant to differ mechanistically or clinically from Vilon or Thymogen is not clearly explained in the sources reviewed; vendor material tends to describe all three broadly as “immune bioregulators” without a specific, sourced distinction in target cell population or claimed effect. This is flagged as an unresolved gap rather than assumed to reflect a meaningful difference.
No confirmed CAS number, PubChem CID, or UNII record was located for Crystagen. It is not FDA approved and does not appear to hold independent pharmaceutical registration in Russia; it circulates as a supplement.
How does it work?
Plain-English explanation
The proposed idea is that Crystagen supports normal immune-system function and cell turnover, consistent with the general bioregulator hypothesis applied to immune tissue. This has not been demonstrated in controlled human studies.
Technical explanation
Consistent with the broader bioregulator framework, the proposed mechanism is short-peptide modulation of gene expression in immune cells (proposed lymphoid tissue targets, per general vendor descriptions). This has not been independently confirmed, and no pharmacokinetic data for oral use was identified. No published data comparing Crystagen’s activity to that of Vilon or Thymogen was located.
Potential benefits and research applications
Immune-system support
What is being investigated: whether Crystagen supports normal immune function, per developer/vendor materials. How the effect might occur: proposed gene-regulatory action in immune tissue, broadly similar in concept to other Khavinson immune peptides. Evidence: limited animal/mechanistic work attributed to the originating Russian group; independent replication was not identified. Strength: weak (Tier 3/4 at best). Limitation: no controlled human immune-outcome data was found, and no source clearly establishes how Crystagen differs functionally from the better-documented Vilon or Thymogen.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Amounts studied in human research
No established or reliably sourced dosing information was identified.
Amounts studied in animal research
Not consistently reported. No extractable, Crystagen-specific animal dose figures were identified in the sources reviewed.
Practitioner and community-reported protocols
Vendor pages commonly describe 10-20 mg oral capsules, one capsule daily, in cycles of roughly 10-20 days, often marketed around seasonal immune support. This is vendor/community-reported (Tier 6) information, and its original clinical source could not be verified.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| General immune support (community use) | Oral capsule | 10-20 mg per capsule | Once daily | Roughly 10-20 day cycles |
Vendor sources commonly describe 10-20 mg oral capsules taken once daily for about 10-20 days.
This is widely repeated online, but its original source could not be verified against any published clinical protocol.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
No systematic human safety data was identified. General risks applicable to unregulated peptide supplements apply: unverified purity and identity, uncertain oral bioavailability, absence of long-term safety monitoring, and supply-chain risks. Anyone with an autoimmune condition or on immune-modulating medication should be aware that no clinical safety data exists for an unregulated immune-marketed peptide like this one.
Regulatory and developmental status
Crystagen is not FDA approved and has no FDA-recognized indication. No independent pharmaceutical registration was identified in Russia; it circulates as a supplement. Status verified as of the review date below.
Frequently asked questions
What is Crystagen?
Crystagen is a short Khavinson-family synthetic peptide marketed as an immune-system bioregulator, sold mainly as an oral supplement.
How is Crystagen different from Vilon or Thymogen?
All three are marketed as immune bioregulators from the same research family, but no source reviewed clearly explains a specific functional distinction between Crystagen and the better-documented Vilon or Thymogen dipeptides. This is treated as an open gap rather than assumed.
What dosage has been studied in humans?
No established or reliably sourced human dosing information was identified.
What dosage commonly circulates online?
Vendors commonly describe 10-20 mg oral capsules taken once daily for roughly 10-20 days; this is vendor/community-reported, not a clinical dose.
Is Crystagen approved by any regulator?
No. No FDA or other formal regulatory approval was identified.
Bottom line
Crystagen is a less-documented immune-focused member of the Khavinson bioregulator family, marketed similarly to but distinct from Vilon and Thymogen without a clearly sourced explanation of how it differs. What underlying research exists is limited to animal/mechanistic work from the originating group, with no independent human clinical evidence or confirmed chemical identifiers.